SEARCH

SEARCH BY CITATION

References

  • 1
    Green M. Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103108.
  • 2
    Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transpl Infect Dis 2001; 3: 8896.
  • 3
    Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lympholiferative disorders in solid organ transplant recipients. Clin Infect Dis 2004; 39: 10161023.
  • 4
    Thorley-Lawson D, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. New Engl J Med 2004; 350: 132837.
  • 5
    Snow A, Martinez O. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7: 271277.
  • 6
    Hadinoto V, Shapiro M, Greenough   et al. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008; 111: 14201427.
  • 7
    Allen UD. The ABC of Epstein-Barr virus infections—Hot topics in infection and immunity in children. Adv Exp Med Biol 2005; 568: 2539.
  • 8
    Opelz G, Dőhler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222230.
  • 9
    Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 7078.
  • 10
    Caillard S, Dharnidharka V, Agoda L et al. Posttransplant lymphoproliferative disorders and renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 12331243.
  • 11
    Webber S A, Green M. Post-transplant lymphoproliferative disorders and malignancy. In: FineRN, WebberSA, OlthoffKM, KellyDA, HarmonWE, eds. Pediatric solid organ transplantation. Massachusetts : Blackwell Publishing, 2007: 114123.
  • 12
    Allen UD, Farkas G, Hébert D et al. Risk Factors for posttransplant lymphoproliferative disease (PTLD) in pediatric patients. Pediatr Transplant 2005; 9: 450455.
  • 13
    Humar A, Malkan G, Moussa G et al. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000; 181: 14501453.
  • 14
    Badley AD, Portela DF, Patel R et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375382.
  • 15
    Martinez M, Gruijl F. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008; 8: 22052211.
  • 16
    Tosato G, Jones K, Breinig MK et al. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993; 91: 28062814
  • 17
    Muti G, Mancini V, Ravelli E, Morra E. Significance of Epstein-Barr virus (EBV) load and Interleukin-10 in post-transplant lymphoproliferative disorders. Leuk Lymphoma 2005; 46: 13971407.
  • 18
    Lee TC, Savoldo B, Barshes NR et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 2006; 20: 389393.
  • 19
    Barshes NR, Lee TR, Goss JA et al. Sic11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation. Transpl Infect Dis 2006; 8: 108112.
  • 20
    Carpentier L, Tapiero B, Alvarez F et al. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferativ disease. J Infect Dis 2003; 188: 18531864.
  • 21
    Preiksaitis JK, Diaz-Mitoma F, Mirzayans F et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166: 986994.
  • 22
    Young L, Alfieri C, Hennessy K et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N EngI J Med 1989; 321: 10801085.
  • 23
    Fanaian N, Cohen C, Waldrop S, Wang J, Shehata BM. EBER: Automated in situ hybridization (ISH) vs. manual ISH and immunohistochemistry (IHC) for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol 2009; 12: 195199.
  • 24
    Young L, Alfieri C, Hennessy K et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N EngI J Med 1989; 321: 10801085.
  • 25
    Hayden RT, Hokanson KM, Pounds SB et al. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. J Clin Microbiol 2008; 46: 157163.
  • 26
    Preiksaitis JK, Pang XL, Fox JD et al. Inter-laboratory comparison of Epstein-Barr virus (EBV) viral load assays. Am J Transplant 2009; 9: 269279.
  • 27
    Hakim H, Gibson C, Pan J et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus (EBV) in peripheral blood. J Clin Microbiol 2007; 45: 21512155.
  • 28
    De Paoli P, Pratesi C, Bortolin MT. The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 2007; 133: 809815.
  • 29
    Stevens SJC, Verschuuren EAM, Verkuulen AWM et al. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831840.
  • 30
    Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: An approach in development. Bone Marrow Transplant 2006; 37: 53946. Review.
  • 31
    Tsai DE, Douglas L, Andreadis C et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: Results of a two-arm prospective trial. Am J Transplant 2008; 8: 10161024.
  • 32
    Gartner BC, Fischinger J, Schafer H, et al. Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease: Recent results. Cancer Res 2002; 159: 4954.
  • 33
    Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 10121019.
  • 34
    Michelson P, Watkins B, Webber SA, Wadowsky R, Michaels MG. Screening for PTLD in lung and heart–lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR. Pediatr Transplant 2008; 12: 464468.
  • 35
    Smets F, Latinne D, Bazin H et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 16031610.
  • 36
    Hopwood PA, Brooks L, Parratt R et al. Persistent Epstein-Barr virus infection: Unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002; 74: 194202.
  • 37
    Bianchi E, Pascual M, Nicod M et al. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation 2008. 85: 707712.
  • 38
    McCormack L, Hany TI, Hübner M et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? Am J Transplant 2006; 6: 17311736.
  • 39
    Swerdlow SH, Webber SA, Ferry JA et al. A post-transplant lymphoproliferative disorders. In: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th Ed. Lyons : International Agency for Research on Cancer/WHO. 2008.
  • 40
    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkins lymphoma: Dissimilarities with lymphoma in adults. Semin Oncol 1980; 7: 332339
  • 41
    Funch DP, Waler AM, Schneidr G et al. Ganciclovir and acyclovir reduce the risk of post-transplant lympoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 28942900.
  • 42
    Humar A, Hébert D, Davies D et al. A multi-center randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against EBV related post-transplant lymphoproliferative disorder (PTLD) in high-risk solid organ transplant recipients. Transplantation 2006; 81: 856861.
  • 43
    Green M, Michaels MG, Katz BZ et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 190612.
  • 44
    Opelz G, Daniel V, Naujokat C et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hogkin lymphoma: A multicentre retrospective analysis. Lancet Oncol 2007; 8: 212218
  • 45
    McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 160411. Erratum in: Transplantation 1999; 68: 909.
  • 46
    Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 22222228.
  • 47
    Van Esser JW, Niesters HG, Van Der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 43644369.
  • 48
    Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev 2004; 18: 193209.
  • 49
    Savoldo B, Gross JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). Blood 2006; 108: 29422949.
  • 50
    Webber SA, Green M. Post-transplant lymphoproliferative disorders and malignancy. In: FineRA, WebberSA, OlthoffKM, KellyDA, HarmonWE, eds. Pediatric Solid Organ Transplantation, 2nd Ed. Massachusetts : Blackwell Publishing, 2007: 114123.
  • 51
    Preiksaitis JK, Cockfield SM. Epstein-Barr virus and lymphoproliferative disease after hematopoietic stem cell or solid organ transplantation. In: BowdenRA, LjungmanP, PayaCV, eds. Transplant Infections, 2nd Ed. Lippincott, Williams and Wilkins, 2003: 326349.
  • 52
    Blaes AH, Peterson BA, Bartlett NL, Dunn DL and Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial. Cancer 2005; 104: 16611667.
  • 53
    Gross TG, Orjuela M, Hayashi R, Cairo MS, Lynch JC. Preliminary results of low-dose chemotherapy and rituximab for pediatric patients with EBV (+), CD20 (+) post-transplant lymphoproliferatuve disease (PTLD) following solid organ transplantation (SOT): A Children's Oncology Group Phase II study. Pediatr Transplant 2009; 13: 109 (Abstract).
  • 54
    Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007; 41: 16481659
  • 55
    Haque T, Wilkie G, Jones M, Higgins C et al. Allogeneic cytotoxic T-cell therapy for EBV positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicellular clinical trial. Blood 2007; 110: 11231131.
  • 56
    Davis CL. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 108118.
  • 57
    Haddad E, Paczesny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1–2 clinical trial. Blood 2001; 97: 15901597.
  • 58
    Green M, Cacciarelli TV, Mazariegos GV et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998; 66: 16411644.
  • 59
    Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 40554063.
  • 60
    Oertel S, Trappe RU, Zeidler K et al. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006; 85: 478484.
  • 61
    Van Esser JWJ, Niesters HGM, Thijsen SFT et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814821.
  • 62
    Bingler MA, Feingold B, Miller SA et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008; 8: 442445
  • 63
    Green M, Soltys K, Rowe DT et al. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatric Transplant 2009; 13: 319323.